Nosocomial cerebral aspergillosis: a report of 3 cases

Scand J Infect Dis. 1996;28(3):317-9. doi: 10.3109/00365549609027182.

Abstract

Cerebral aspergillosis carries a mortality rate close to 100%, especially in immunocompromised patients. We describe 3 patients who contracted cerebral aspergillosis after neurosurgery, 2 of whom survived after exhaustive surgical treatment and medical treatment with high doses of amphotericin B (once liposomal), 5-fluorocytosine and itraconazole. We review the few non-fatal cases of cerebral aspergillosis reported. We consider that surgical excision must be complete and repeated if necessary, always in combination with medical treatment.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Amphotericin B / administration & dosage
  • Amphotericin B / therapeutic use*
  • Antifungal Agents / therapeutic use*
  • Aspergillosis / diagnosis*
  • Aspergillosis / drug therapy*
  • Aspergillosis / mortality
  • Brain / microbiology*
  • Cross Infection / diagnosis*
  • Cross Infection / drug therapy*
  • Drug Carriers
  • Drug Therapy, Combination
  • Female
  • Flucytosine / therapeutic use*
  • Humans
  • Immunocompromised Host
  • Itraconazole / administration & dosage
  • Itraconazole / therapeutic use*
  • Liposomes
  • Male
  • Neurosurgery

Substances

  • Antifungal Agents
  • Drug Carriers
  • Liposomes
  • Itraconazole
  • Amphotericin B
  • Flucytosine